Society: AASLD

Background: Cirrhosis is a major contributor of morbidity and mortality in patients with chronic liver disease globally. The disease burden of viral-related cirrhosis has decreased, related to advancements in prevention and treatments while the prevalence of non-alcoholic fatty liver disease and alcohol-associated cirrhosis has increased mirroring the metabolic disease epidemic. Nevertheless, the relative implication of the transition in the predominant etiology of cirrhosis has yet to be examined between males and females. This study aims to present sex differences in the disease burden of cirrhosis from 2010-2019.

Methods: Using the Global Burden of Disease Study 2019, we evaluated the temporal trends of cirrhosis incidence between the sexes. Yearly frequencies and age-standardized rates (ASR) of incidence, death, and disability-adjusted life-years (DALYs) associated with cirrhosis from 2010-2019 were estimated and stratified by sex, region, country, socio-demographic index (SDI), and cirrhosis etiology.

Results: In 2019, the overall burden of cirrhosis was higher in males compared to females. There were 1,206,125 incident cases, 969,068 deaths, and 31,781,079 DALYs due to cirrhosis in males, and 845,429 incident cases, 502,944 deaths, and 14,408,336 DALYs due to cirrhosis in females, respectively (Figure 1A-D). From 2010-2019, there was an 11% increase in incident cirrhosis cases in males and a 16% increase in females. The frequency of cirrhosis-related deaths also increased by 9% in males and 12% in females. Incidence ASR of cirrhosis increased in females while remaining stable in males. However, death ASRs declined in both males and females in all regions except for the Americas where it remained stable. The largest increase in incident cirrhosis cases was in low SDI countries for both males (+37%) and females (+32%). While the leading cause of incident cirrhosis cases was HCV in both sexes, NASH was the fastest-growing etiology of incident cirrhosis cases in both males (+23%) and females (+30%). The leading cause of cirrhosis-related deaths was alcohol and HCV in males and females respectively (Figure 1E). Furthermore, death ASRs decreased for all etiologies in both sexes, except for NASH-related cirrhosis which remained stable.

Conclusion: In summary, the global burden of cirrhosis is substantially higher in males compared to females. Age-adjusted mortality declined for all etiologies of liver disease for males and females, except in NASH. The age-adjusted incidence rates of NASH cirrhosis in females exceeded that of males, while age-adjusted mortality rates in females approached that of males. Measures are required to tackle obesity and diabetes to reduce the global burden of NASH cirrhosis in both males and females.

<b>Figure 1 </b><br /> <b>(A</b>): Frequency of incident cirrhosis cases in males versus females from 2010 to 2019, by etiology of liver disease<br /> <b>(B</b>): Frequency of cirrhosis-related deaths in males versus females from 2010 to 2019, by etiology of liver disease<br /> <b>(C): </b>Frequency of cirrhosis-related deaths in males versus females in 2019, by etiology of liver disease<br /> <b>(D): </b>Frequency of cirrhosis-related deaths in males versus females in 2019, by World Health Organization region<br /> <b>(E): </b>Contribution of global cirrhosis-related deaths in male versus females in 2019, by etiology of liver disease

Figure 1
(A): Frequency of incident cirrhosis cases in males versus females from 2010 to 2019, by etiology of liver disease
(B): Frequency of cirrhosis-related deaths in males versus females from 2010 to 2019, by etiology of liver disease
(C): Frequency of cirrhosis-related deaths in males versus females in 2019, by etiology of liver disease
(D): Frequency of cirrhosis-related deaths in males versus females in 2019, by World Health Organization region
(E): Contribution of global cirrhosis-related deaths in male versus females in 2019, by etiology of liver disease

Background: Despite broad acceptance of Baveno VI criteria for non-invasive prediction of varices needing treatment (VNT), its adoption in community practices is limited due to lack of easy access to transient elastography (TE) in the United States. Our group has recently established a deep learning model using 12-lead electrocardiograms (ECG) to accurately detect the presence and severity of cirrhosis. Given its wide availability and low cost, we aimed to determine whether an ECG-enabled model in addition to platelet count could be used to spare screening endoscopies (EGD) while maintaining an acceptable missed rate of VNT to less than 5%.

Methods: Adult patients with cirrhosis (based on ICD10 codes) who underwent screening EGD at Mayo Clinic, Rochester from 1/2020-1/2022 were identified. Data were then extracted from the ProVation reporting database to identify two distinct groups: those without or with small (< 5 mm) varices, and those with large (>5 mm) varices. For each patient, the Detection of Undiagnosed Liver Cirrhosis via ECG (DULCE) score was generated using a 12-lead ECG completed nearest to the date of their EGD. Logistic regression models were fit to predict the presence of large varices based on platelets and DULCE score. An ROC curve was produced and a threshold to maximize specificity while retaining a sensitivity >=0.95 was identified.

Results: A total of 1,086 patients with cirrhosis undergoing screening EGD were included. Median age 61, 58.6% males and mean MELD-Na score 16. A significant association between platelet count (OR 0.68, CI 0.56, 0.82) and DULCE score (OR 2.24, CI 1.40, 3.60) with presence of large esophageal varices was found (table 1). A combined model with platelet count and DULCE score was predictive of large esophageal varices with an area under the receiver operating characteristic curve (AUC) of 0.636. For this study, large varices were considered VNT. To maintain the acceptable missed VNT rate, we identified a threshold to achieve 95% sensitivity for VNT. When applying the determined threshold, the combined DULCE and platelet model would result in 129 spared endoscopies (12.5%) and 11 missed VNT (1.1%) within this cohort (Table 2).

Conclusions: An electrocardiogram-based deep learning model may be a useful adjunctive tool for predicting the presence of high-risk esophageal varices in patients with cirrhosis. Compared to the Baveno VI criteria, our model offers the potential to use a widely-available test (ECG) rather than specialized liver stiffness measurement for non-invasive prediction of esophageal varices and thus reduce the need for screening EGD in low-risk patients.

<b>Table 1:</b> Baseline characteristics and DULCE scores for patients in the two defined groups.

Table 1: Baseline characteristics and DULCE scores for patients in the two defined groups.

<b>Table 2: </b>Performance of the combined model (DULCE + platelet) for avoiding upper endoscopy.

Table 2: Performance of the combined model (DULCE + platelet) for avoiding upper endoscopy.

BACKGROUND: Acute variceal bleeding (AVB) is a lethal complication in patients with liver cirrhosis. We performed a nationwide AVB audit to review the clinical outcome and the real-world compliance of AASLD cirrhosis quality measures of AVB in Singapore.

METHODS: All public hospitals in Singapore were invited to participate in this first nationwide AVB audit. We reviewed cirrhosis patients admitted for AVB from January 2015 to December 2020. Individual patient data on baseline characteristics and clinical outcomes were reviewed and extracted using unified data frame. The primary outcome was the real-world compliance rate with the AASLD AVB quality measures (early endoscopy within 12hours (<12hr), somatostatin infusion<12hr, prophylactic antibiotics<12hr, and receiving the combination of endoscopic hemostasis and NSBB post endoscopy). The secondary outcome was the clinical outcome of AVB based on the Baveno-VII consensus (early rebleeding within 5 days, mortality at 6 weeks).

RESULTS: This nationwide variceal bleeding audit included the largest cohort of cirrhosis patients with AVB to-date (n=691) from six public hospitals in Singapore. The mean age was 62 years, 73.6% were male, with ethnicity distribution similar to the general Singapore population. The mean MELD score was 13.5 (±5.9). The mean CTP score was 7.1 (±1.3), among which, 35.4% was CTP-A, 58.4% was CTP-B and 6.2% was CTP-C. At baseline, 18.0% had prior variceal bleeding, 28.7% had ascites requiring diuretics, 34.5% had prior HE, 26.7% had HCC and 17.0% had PVT.

The real-world compliance to the AASLD AVB quality measures in Singapore was high: early endoscopy<12hr (81.2%), somatostatin<12hr (90.8%), prophylactic antibiotic<12hr (91.4%); 84.0% received both endoscopic ligation/sclerotherapy and NSBB during AVB. Endoscopic hemostasis was achieved in 92.5% of AVB, and only 7% required salvage therapy (TIPSS 2.5%, SB tube 4.9%). Only 3.7% of AVB patients eligible for pre-emptive TIPSS (p-TIPSS) underwent p-TIPSS. Overall, the 5-days rebleeding rate was 6.2%; 6-weeks mortality rate was 13.7%, and 1-year mortality rate was 26.2%. Patients who received both endoscopic ligation/sclerotherapy and NSBB for AVB were associated with significantly lower rates of 5-day rebleeding (4.8% vs 10.9%, p=0.009) and 6-week mortality (8.3% vs 36.4%, p<0.001). Despite high compliance with the recommended process measures, patients with CTP-C remains at a higher risk of rebleeding, ACLF, 6-week- and 1-year mortality, (Table 1).

CONCLUSION: The Singapore Nationwide Acute Variceal Bleeding Audit demonstrates high compliance with the AASLD cirrhosis quality measures for managing AVB. Despite the low uptake of pre-emptive TIPSS, the outcomes of AVB are similar to expert hepatology centres globally. Further work is needed to improve the outcomes in CTP class C patients with AVB.

Introduction:
Management of Gastric variceal (GV) hemorrhage is more complicated than management of esophageal variceal (EV) hemorrhage, resulting in significantly higher morbidity and mortality. Most recommendations for managing GV hemorrhage are extrapolated from studies where most participants had EV and are based on expert opinion rather than evidence-based medicine. We aim to compare the outcomes of Endoscopic Variceal Ligation (EVL), Transhepatic Intrahepatic Portosystemic Shunt (TIPS), and Balloon-occluded Retrograde Transvenous Obliteration (BRTO) in the management of bleeding GV.

Methods:
We utilized the National Inpatient Sample (NIS) database from January 2016 to December 2019 to include cases involving GV hemorrhage. Cases were further stratified based on the intervention for EV hemorrhage, including EVL, TIPS, and BRTO. Chi-square was used for categorical data, and the Kruskal-Wallis test was used for continuous data. All analyses were performed using Statistical software for data science (STATA) version 16.0.

Results:
Our study identified 7,160 hospitalizations with a primary diagnosis of GV hemorrhage who underwent the interventions of interest. The median age for hospitalization was 58 years (Interquartile range (IQR) 50-66). The median hospital stay was five days (IQR 3-7 days), with the TIPS/BRTO cohort being the longest (P < 0.001). The median hospitalization charge was $72476 ($36918 -$138897), with the highest being the TIPS/BRTO cohort (P < 0.001). EVL was performed in 69.83%, TIPS in 8.72%, and BRTO in 4.88%. Patients with liver cirrhosis had a higher frequency of undergoing BRTO (68.6%), followed by TIPS (64.0%) and EGD + TIPS (63.7%) (P < 0.001). Patients with liver cirrhosis secondary to alcoholism had a higher prevalence of TIPS (62.4%), followed by EGD + TIPS (69.4%) and BRTO (52.9%) (P < 0.001). Septic shock was most prevalent in hospitalizations with TIPS (12%), followed by EGD + TIPS (9.5%), BRTO (7.1%), EVL (5.7%), and EGD + BRTO (2.8%) (P < 0.001). There was no difference in acute renal failure (ARF) among all three cohorts (P = 0.11). Overall, inpatient mortality was 6.5%. Mortality was highest in the TIPS cohort (8.8%), followed by BRTO (7.1%), EGD + TIPS (6.5%), EVL (6.2%), and EGD + BRTO (2.8%) (P < 0.001). Hospitalizations undergoing TIPS had a higher association with inpatient mortality than EVL (Odds ratio 1.39 [95% Confidence Interval 1.02-1.91], P = 0.037).

Conclusion:
Patients undergoing TIPS and BRTO have an increased inpatient mortality rate, longer hospital stays, and higher hospitalization charges. They also have a higher rate of inpatient complications when compared to EVL. More studies involving newer treatment strategies, including endoscopic ultrasound-guided glue/cyanoacrylate and coil embolization, are needed to improve outcomes in GV hemorrhage.

Inpatient mortality in Gastric variceal bleeding based on therapy

Inpatient mortality in Gastric variceal bleeding based on therapy

Summarization of patient characteristics and inpatient complications

Summarization of patient characteristics and inpatient complications

Aim/background. Trans Jugular intra-hepatic Porto Systemic Shunt (TIPS) can be a lifesaving procedure for esophageal variceal bleeding.[AW1] Safety and benefits of TIPS in the elder population (≥ 65 years) are controversial.

Aim. The primary aim to Assess the mortality outcomes of cirrhosis subjects with age ≥65 who had undergone the TIPS procedure for variceal bleeding. The secondary aim assesses hospital resource utilization.

Methods. We utilized national readmission data from 2010-2014 to study TIPS hospitalization outcomes in cirrhotic subjects aged 65-80 (advanced age) admitted with esophageal variceal bleeding. We excluded liver transplant recipients, hepatocellular carcinoma (HCC), and subjects currently on the liver transplant list. Outcomes of TIPS in relationship with age were computed in a multivariate model adjusted for gender, etiology of liver disease, comorbidities, and hepatic decompensatory events.

Results. There were 6,338 hospital admissions related to TIPS reported between 2010-2014. Of the total 1,102 were in the advanced age group (mean age: 70.0 ± 3.6). Female representation was higher in this group (43% vs. 30%, p <0.001). Non-alcoholic fatty liver disease and autoimmune disease were more common in the advanced-age population whereas hepatitis C and alcoholic liver disease were more common in the younger population. Multivariable analysis showed that advanced-age individuals who underwent TIPS for variceal bleeding had higher mortality (OR: 1.78, 95% CI: 1.6 – 2.71. p=0.01). Length of stay, hospitalization cost, and 30-day readmission was similar between the two age groups. After multivariable adjustment CHF (OR: 2.21, 95% CI 1.13 – 4.32, p=0.02) and CAD (OR: 3.13, 95% CI: 1.95 – 5.04, p<0.001) had a higher association in the advanced age group. TIPS hospitalization trends in the advanced age population increased from 2010 to 2014 (12.3% to 22.3%) but the mortality (14.4% to 6.7%) and 30-day readmission improved (25.6% to 19.1%)

Conclusion. Among the advanced age group, women had higher representation than the younger group. This population had higher mortality, CHF, and CAD despite similar hospital resource utilization as compared to the younger population. We suggest that advanced age group subjects should undergo thorough cardiac risk stratification prior to the consideration of TIPS.

Table-1 Demographics

Adil Memon

Appearances